Overview

Single-dose AQ001S PK Study in Healthy Volunteers

Status:
Recruiting

Trial end date:
2022-02-28

Target enrollment:

Participant gender:

Summary

This is a randomized, open label, single-center, single-dose, four-period crossover clinical study to assess the pharmacokinetic profile and safety of a budesonide inhalation solution (AQ001S) compared to a budesonide inhalation suspension (comparator) in healthy volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

Aquilon Pharmaceuticals S.A.

Treatments:

Budesonide